MedTrace Logo

Humoral Immunity Study After a Booster Dose of Soberana Plus (FINLAY-FR-1A) Vaccine Against COVID-19

NCT05689177 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-02-01

No results posted yet for this study

Summary

To evaluate the dynamics of IgG levels to the SARS-CoV-2 virus after a booster dose of Soberana Plus vaccine.

Conditions

  • Humoral Immunity

Interventions

BIOLOGICAL

Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)

Booster dose administration

Sponsors & Collaborators

  • Gomel State Medical University

    lead OTHER

Principal Investigators

  • Igor Stoma, MD · Gomel state medical university, Gomel, Province, Belarus, 246000

  • Olga Osipkina · Gomel State Medical University, Gomel, Province, Belarus, 246000

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-09
Primary Completion
2023-03-10
Completion
2023-07-28

Countries

  • Belarus

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05689177 on ClinicalTrials.gov